Safety and Efficacy of Once-Weekly Carfilzomib (K) Dosing in Frail Patients (pts): A Subgroup Analysis from the Phase 3 ARROW Study

被引：0

作者：

Mateos, Maria-Victoria ^{[1
]}

Ludwig, Heinz ^{[2
]}

Kumar, Shaji ^{[3
]}

Rosenbaum, Cara ^{[4
]}

Huang, Mei ^{[5
]}

Goldrick, Amanda ^{[5
]}

Blaedel, Julie ^{[5
]}

Dimopoulos, Meletios ^{[6
]}

机构：

[1] Univ Hosp Salamanca, IBSAL, Salamanca, Spain

[2] Wilhelminenspital Stadt Wien, Wilhelminen Canc Res Inst, Vienna, Austria

[3] Mayo Clin, Rochester, MN USA

[4] Weill Cornell Med, New York, NY USA

[5] Amgen Inc, Thousand Oaks, CA 91320 USA

[6] Univ Athens, Sch Med, Athens, Greece

来源：

关键词：

multiple myeloma; carfilzomib; phase; 3; frailty; relapsed; refractory; MM;

D O I：

10.1016/j.clml.2019.07.300

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-055

引用

页码：S320 / S321

页数：2